Identifying patients with type 2 diabetes who might benefit from insulin pump therapy: Literature review, clinical opportunities, potential benefits and challenges

The global prevalence and increasing incidence rates of type 2 diabetes (T2D) have rippling effects on healthcare costs and diminishing quality of life. Despite advances in technology, continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is rarely being recommended by healthcare professionals and is underutilized in T2D management. This review analyses the available literature on CSII use in T2D patients. In addition, it discusses which groups of patients may benefit from CSII, identifies potential challenges associated with CSII use, and suggests future directions for research to expand the applicability of this technology to the broader T2D population.

Automated summary

The global prevalence and increasing incidence rates of type 2 diabetes (T2D) have significant impacts on healthcare costs and quality of life. However, the use of continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is underutilized in T2D management despite technological advances. This review examines the literature on CSII use in T2D patients, discusses potential benefits for specific patient groups, identifies challenges associated with CSII use, and proposes future research directions to expand its applicability to a broader T2D population.